Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy

Dávid Dózsai¹, Tamás Ecseri¹, István Csonka¹, István Gárgyán¹, Péter Doró² and Ákos Csonka¹*

Abstract

Background: Atypical femoral fracture is one of the many complications after the long-term use of bisphosphonates. The American Society for Bone and Mineral Research has officially excluded periprosthetic femoral fractures (PFFs) from the definition of atypical femoral fractures (AFFs). Several case reports found that PFFs can occur with characteristics similar to those of AFFs. The purpose of our study was to evaluate the proportion of atypical fractures among Vancouver type B1 fractures, and to determine the association between the long-term use of bisphosphonates and the occurrence of atypical periprosthetic femoral fractures (APFFs).

Methods: In this retrospective study, we reviewed 41 patients with Vancouver type B1 periprosthetic fractures between January 1, 2011 and December 31, 2018. We classified them into two groups, namely atypical and typical PFFs, based on the fracture morphology. We noted the proportion of atypical periprosthetic fractures among B1 fractures and identified risk factors.

Results: Among the 41 PFFs, 5 (13%) fractures were classified as atypical PFF based on the radiological characteristics. The longer duration of bisphosphonate use was probably the only independent risk factor that significantly increases the occurrence of APFF (p = 0.03, 0.08 (CI 0.008 – 0.16)). There were no significant differences in age, gender, body mass index, comorbidities, corticosteroid use, positioning of the femoral stem, the method of fixation (cemented or cementless) and time lapse from before the primary prosthesis implantation to the PFF in the development of atypical fracture type.

Conclusions: There seems to be a correlation between the long-term intake of bisphosphonates and the atypical periprosthetic fracture. Atypical femoral fracture can also occur in the periprosthetic form.

(Continued on next page)
Introduction

Today, osteoporosis is a disease that affects many millions of people worldwide. About 7-10% of the Hungarian population suffer from it [1]. The use of bisphosphonates has significantly reduced the risk of osteoporotic fractures and hence it has reduced the burden of health care costs [2].

Bisphosphonates have been known to have beneficial effects on the skeletal system such as the reduced risk of fracture. They inhibit resorption of the bone by blocking the action of osteoclasts, so the development of fractures is decreased by minimizing bone loss [3, 4]. Microfractures, forming in the bone, are decreasing indirectly; but the replacement of previously developed microfractures with a new bone matrix is also impaired. This has led to the appearance of atypical femoral fractures (AFF), as a new type of fracture, caused by an artificially developed low bone turnover due to the long-term intake of bisphosphonates [5]. Atypical femoral fracture (AFF) is a stress fracture occurring with low energy or no trauma and it has a characteristic radiographic appearance (Fig. 1) [6]. With atypical subtrochanteric and middle third femoral fractures, periprosthetic fractures should be treated as exclusion criteria based on the recommendation of the American Society for Bone and Mineral Research, published in 2014 [6]. Over the past few years, several case reports have stated that periprosthetic femoral fractures (PFFs) can occur with similar features to those of atypical femoral fractures (AFFs) arising from the long-term use of bisphosphonates (Fig. 2) [7–11]. Atypical periprosthetic femoral fractures (APFFs) are prevalent in the older generation because it is common to have joint implants in this population, they more likely to suffer from osteoporosis, and to have other comorbidities (e.g., diabetes, vitamin D deficiency and the use of the proton pump inhibitor) in their medical record [12]. To the best of our knowledge, the main principal cause, etiology, diagnostic criteria and therapeutic recommendations of APFFs still have not been clearly defined [10].

In our study, we examined one of the possible side-effects of the long-term intake of bisphosphonates on the skeletal system and the incidence of atypical periprosthetic femoral fractures. We analyzed the prevalence of atypical periprosthetic fractures falling into the class of Vancouver type B1 fractures, and we looked for a correlation between the long-term use of bisphosphonate and APFF.

Methods

We carried out a retrospective study between 1st January, 2011 and 31st December, 2018 at the Traumatology Department of University of Szeged. We reviewed the medical records and radiographs of 109 patients with hip replacements who had periprosthetic fractures.
Fig. 2  

a  76-year-old female patient with an atypical periprosthetic femoral fracture, who took bisphosphonates for 11 years.  
b  Postoperative x-ray of the atypical fracture (operative fixation method with an 18 hole locking compression plate and 2 pieces of attachment).  
c  X-ray of a healed atypical fracture after 1 year.

Table 1  Flow diagram of the retrospective study

| Patients with periprosthetic fracture based on Vancouver classification between January 1, 2011 and December 31, 2018 (n=109) |
|---|
| Exclusion criteria: |
| 1. Polytraumatized patient (n=15) |
| 2. Incomplete medical record (n=10) |
| 3. Vancouver type A fracture (n=2) |
| 4. Vancouver type C fracture (n=25) |
| Patients with Vancouver type B periprosthetic femoral fracture after low energy trauma (n=57) |
| Vancouver B1 (n=41, 72%) |
| Vancouver B2 (n=12, 22%) |
| Vancouver B3 (n=4, 6%) |
| Typical PFF (n=36, 87%) |
| Atypical PFF (n=5, 13%) |
afterwards. Inclusion criteria were patients who were over 50 years and had had a low energy trauma.

Out of 109 patients, 15 patients who were polytrauma-tized and 10 patients with incomplete medical records were excluded. After a radiologic review, we excluded patients who had Vancouver type A (n = 2), B2 (n = 12), B3 (n = 4) or C (n = 25) fractures. The remaining 41 patients (Vancouver type B1 periprosthetic fracture) were subjects of our study (see Table 1).

First of all, we took into account the age, gender, body mass index (BMI), comorbidities (e.g., hypertension, diabetes, rheumatoid arthritis, thyroid disease, neurologic disease, malignancy, osteoporosis) and the use of bisphosphonate and glucocorticoid. We evaluated the position of the femoral stem on the radiographs and the method of fixation (cemented or cementless stem). Then we determined the interval between PFF and prior hip arthroplasty and the time of bone formation. In every case the bisphosphonate therapy applied was alendronate.

In order to establish the diagnosis of atypical femoral fractures, we used the revised criteria of the American Bone and Mineral Research Taskforce (see Table 2) [6]. A diagnosis of atypical femoral fractures was made when four or more of the major criteria were met.

### Table 2 ASBMR Task Force 2013 Revised Case Definition of AFFs [6]

| Major criteria | Minor criteria | Exclusion criteria |
|----------------|----------------|-------------------|
| - minimal or no trauma | - increase in cortical thickness of the femoral diaphyses | - femoral neck fracture |
| - Transverse or slightly oblique fracture line | - Unilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thigh | - intertrochanteric fractures with spiral subtrochanteric extension |
| - Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex | - Bilateral incomplete or complete diaphysis fractures | - periprosthetic fractures |
| - non or minimally comminuted fracture | - Delayed healing | - pathologic fractures related to primary or metastatic bone tumors and miscellaneous bone diseases |
| - Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site | | |

### Table 3 Demographics of typical PFF group and atypical PFF group

| Vancouver type B1 fracture distribution | Typical PFF (n = 36, 87%) | % | Atypical PFF (n = 5, 13%) | % | p-value |
|-----------------------------------------|---------------------------|---|---------------------------|---|--------|
| Mean age                                | 79.5 (54-94)              |   | 80 (67-85)                |   | 0.24   |
| Gender (male/female)                    | 9/27                      |   | 0/5                       |   | 0.26   |
| BMI – body mass index                   | 24.9 ± 3.3                |   | 23.2 ± 1.8                |   | 0.53   |
| **Chronic diseases**                    |                           |   |                           |   |        |
| Diabetes                                | 7                         | 19.44% | 0 | 0% | 0.37   |
| Rheumatoid arthritis                    | 1                         | 2.78%  | 1 | 20% | 0.21   |
| Hypertension                            | 35                        | 97.22% | 5 | 100.0% | 0.87   |
| Thyroid disease                         | 5                         | 13.89% | 2 | 40% | 0.66   |
| Malignancy                              | 3                         | 8.33%  | 0 | 0% | 0.62   |
| Neurologic disease                      | 9                         | 25.00% | 2 | 40% | 0.29   |
| Osteoporosis                            | 16                        | 44.44% | 4 | 80% | 0.20   |
| History of bisphosphonate use           | 5                         | 13.88% | 4 | 80% | 0.01   |
| Duration of bisphosphonate use (years average) | 4 ± 0.7 |   | 8.2 ± 5.5 |   | 0.01   |
| Corticosteroid use                      | 1                         | 2.78%  | 0 | 0% | 0.87   |
| **Stem position**                       |                           |   |                           |   |        |
| Central                                 | 32                        | 88.89% | 4 | 80% | 0.39   |
| Varus                                   | 2                         | 2.78%  | 1 | 20% | 0.29   |
| Valgus                                  | 2                         | 2.78%  | 0 | 0% | 0.76   |
| Cemented stem                           | 31                        | 86.11% | 5 | 100% | 0.50   |
| Cementless stem                         | 5                         | 13.89% | 0 | 0% | 0.50   |
| Duration of healing process (months average) | 5.7 ± 1.4 |   | 9.2 ± 4.7 |   | 0.27   |
| Interval between prior arthroplasty and PFF (years average) | 10 ± 8 |   | 6 ± 3.5 |   | 0.26   |
We applied locking compression plates (LCP) in each case to fixate the atypical periprosthetic fractures, completing it with cerclage, cable and attachment, where necessary (Fig. 2).

Statistics
Univariate statistical comparisons were performed using the Mann-Whitney U test for continuous variables, and Fisher ’ s Exact test for categorized data. The confidence level was set at 95%. Then, a multivariable regression analysis was performed for 7 risk factors that displayed the most significant value based on a univariate comparison. Also the chosen risk factors for the multivariable regression analysis were the most common in the literature as main risk factors of AFF (eg. RA, BP use, gender (female), diabetes). All the analyses were conducted using Windows Microsoft Excel (2016 version).

Results
Among 41 Vancouver type B1 PPFs, 5 (13%) were classified as atypical PPF. The mean age of patients with typical PPFs was 79.5 (54-94) years, compared to 80 (76-85) years for patients with atypical PPFs. As regards gender, there were 27 men and 14 women. Atypical fractures occurred only in women (n = 5). There were no significant differences in age, gender, BMI, comorbidities, the proportion of osteoporosis (T score < –2.5), positioning of the femoral stem and the method of fixation between the typical PPF and atypical PPF group. In terms of gender, atypical fractures occurred only in women, which presumably did not play any significant role in the development of this fracture type (p = 0.26). There was no significant difference between the two groups (p = 0.27) regarding the length of time of bone development, but the upper leg bone took longer to heal in the atypical group. We observed a significant correlation between the history of bisphosphonate use (p = 0.01) and the duration of bisphosphonate therapy (p = 0.01) in the development of AFF in our univariate analysis.

The only independent significant risk factor was probably the duration of bisphosphonate use (p = 0.03, 0.08 (CI 0.008 – 0.16)) in APFF in terms of age, gender, history of rheumatoid arthritis and osteoporosis, the duration and history of bisphosphonate use and the time lapse from before the primary prosthesis implantation to the PFF in the multivariate regression analysis. In our regression model we got an R squared value of 0.43 (see Table 3).

Discussion
Atypical femoral fractures typically occur as stress fractures. Prodromal pain in the thigh preceding the fracture was described previously in the literature. Radiological characteristics are usually bilateral, including microfracture and the lateral cortex thickening [6]. Radiography should include bilateral views of the full length of each femur in the case of atypical femoral fractures arising from lateral cortex thickening and microfracture, which might suggest impending fractures. It is known that the frequency of late periprosthetic fracture is the highest in the case of fixation of the cemented stem. However, periprosthetic fracture usually occurs within six months in cementless hip arthroplasty, but it is not correlated with the atypical fracture type [13]. Atypical fractures occurred in cemented hip arthroplasty, but they did not play any significant role in the development of an atypical fracture type (p = 0.50). In terms of positioning of the stem, it is known that varus positioning increases the stress and fractures are more likely to occur at the tip of the femoral stem [14].

None of the positions (central, varus, valgus) played a significant role in the development of atypical fractures related to the location of the prosthetic stem. The surgical treatment of the periprosthetic Vancouver type B1 fractures is based on the LCP systems, and these can be combined with cerclage, cable or plate attachment, and moreover, allograft can be implanted in order to stabilize the fixation of the fracture in the case of bone loss [15, 16].

In our study no significant difference was found between the atypical periprosthetic B1 fractures and the typical periprosthetic fractures in terms of fixation, but it is should be recalled that a delayed healing process, higher mortality rate and more complications can occur after osteosynthesis [6, 17].

PPFs represent a big challenge for orthopedic surgeons because the observed frequency of these fractures due to the rising number of patients with prosthetics is increasing [15]. The American Society for Bone and Mineral Research excluded periprosthetic fractures in the case of atypical fracture, but they were mainly published as case studies in the literature [7--9, 18].

In this study among the 41 PPFs, 5 fractures were classified as atypical PFF based on the radiological characteristics and among these, 4 were associated with long-term bisphosphonate use. This retrospective study has some limitations, such as the small patient number, incomplete patient history (no knowledge of prodromal pain in the thigh) and the lack of radiographs of the contralateral femur. By case definition according to the second, revised recommendation of the American Society for Bone and Mineral Research no association was found between atypical fractures and other comorbidities or the use of drugs such as bisphosphonates. Case studies report a significant association between AFFs and bisphosphonate use; even though the strength of the association and size of the effect vary, just the relative
risk of patients with AFFs taking BPs is high [6, 19]. However, long-term use may be associated with AFFs [6]. Although the use of bisphosphonate was excluded in the case definitions of AFF, their long-term use is still considered as one of the most important pathophysio-logic mechanisms of AFF. As reported in the literature, there is a strong association between atypical femoral fracture and bisphosphonate use especially in the case of long-term treatment (> 5 years) [17, 20].

A strong correlation was found between those taking bisphosphonates and atypical fractures including periprosthetic types according to a multicentric study that processed 10 years of follow-up studies of the National Trauma Registries in Canada and the USA [10]. Level I evidence might be needed to demonstrate that bisphosphonates play a leading role in the development of atypical fractures. In the literature, studies on atypical periprosthetic fractures are mainly case reports [10, 17, 21].

In our study, the long-term use of bisphosphonate seemed to be the only independent risk factor associated with atypical periprosthetic femoral fractures. Previous related publications arrived at a similar conclusion [8–10, 12].

Conclusions
On the basis of our results and the literature it appears that atypical femoral fractures can occur in the periprosthetic form and display a significant correlation with bisphosphonate use [9, 17].

The medical management of atypical fractures is a big challenge and the outcome is much poorer than that of the typical fractures because of the delayed healing process, poor bone consolidation, difficulty of fracture fixation and high mortality rate [22–24]. Nevertheless, our results indicate that clinicians should consider the possibility of atypical fracture, when periprosthetic Vancouver type B1 fracture occurred if long-term bisphosphonate therapy is mentioned in the patient history. Bisphosphonate therapy should be applied carefully, always bearing in mind the risk-benefit ratio. Keeping up to date with the latest antiresorptive medications and follow up-care of patients is crucial for correct patient treatment.

Acknowledgements
Not applicable.

Authors’ contributions
DD: Wrote the criteria (exclusion, inclusion), collected and analyzed the data, performed the intra- and inter-reader analysis, and wrote the paper. TE: collected and analyzed the data, supervised the data collection and analysis. ICS: supervised the data collection and analysis, revised the paper. IG: Organized the study, revised the protocol, performed the intra- and inter-reader analysis. PD: Revised the paper. ACS: Planned the study, wrote the study protocol, wrote and revised the paper. All authors read and approved the final manuscript.

Funding
This study was not founded by any organization or person.

Availability of data and materials
Raw data were generated at the university hospital. Derived data supporting the findings of this study are available from the corresponding author on request.

Ethics approval and consent to participate
This is a retrospective study, all the data having been collected from medical databases and radiographic analyses. Permission to gather and process data was obtained prior to the commencement of the study, by the university ethical committee (Study number 22/2019-SZTE).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Traumatology Department, University of Szeged, Semmelweis u. 6, Szeged 6725, Hungary. 2Clinical Pharmacy Department, University of Szeged, Szikra utca 8, Szeged 6725, Hungary.

Received: 23 June 2020 Accepted: 1 September 2020
Published online: 15 September 2020

References
1. Szathmári M. Evaluation of fracture risk in osteoporosis. Orv Hetil. 2011;152:1304–11. https://doi.org/10.10156/orv.2011.29191.
2. Adams AL, Adams JL, Raebel MA, et al. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. J Bone Miner Res. 2018;33:1252–9. https://doi.org/10.1002/jbmr.3420.
3. Cremers S, Drake MT, Ebertin FH, et al. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85:1052–62.
4. Harvey NC, Curtis EM, Dennison EM, Cooper C. The epidemiology of osteoporotic fractures. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism; 2018. p. 398–404.
5. Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and Benefits of Bisphosphonate Therapies. J Cell Biochem. 2016;117:20–8. https://doi.org/10.1002/jcb.25266.
6. Shane E, Buur D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J. Bone Miner. Res. 2014;29:1–23.
7. Woo SB, Choi ST, Chan WL. Atypical periprosthatic femoral fracture: A case report. J Orthop Surg. 2016;24:269–72. https://doi.org/10.1177/160240021030.
8. Miura T, Kijima H, Tani T, et al. Two Cases of Periprosthetic Atypical Femoral Fractures in Patients on Long-term Bisphosphonate Treatment. Case Rep Surg. 2019;2019:1–6. https://doi.org/10.1155/2019/9845320.
9. Lee YK, Park CH, Kim KC, et al. Frequency and associated factor of atypical periprosthetic femoral fracture after hip arthroplasty. Injury. 2018;49:2264–8. https://doi.org/10.1016/j.injury.2018.09.014.
10. Robinson JDD, Leighton RK, Task K, et al. Atypical Periprosthetic Atypical Femoral Fractures in Patients on Long-term Bisphosphonates: A Multicenter Retrospective Review. J Orthop Trauma. 2016;30:170–6.
11. Lepri AC, Capone A, Del Prete A, et al. Atypical femur fractures. Clin Cases Miner Bone Metab. 2018;15:43–59.
12. Abdel MP, Watts CD, Houdek MT, et al. Epidemiology of periprosthetic fracture of the femur in 32 644 primary total hip arthroplasties: A 40-year experience. Bone Jt J. 2016;98B:461–7. https://doi.org/10.1302/0301-620X.98B4.37201.
13. Tamaki T, Jonishi K, Miura Y, et al. Cementless Tapered-Wedge Stem Length Affects the Risk of Periprosthetic Femoral Fractures in Direct Anterior Total Hip Arthroplasty. J Arthroplasty. 2018;33:805–9. https://doi.org/10.1016/j.arth.2017.09.065.
14. Leclerc JT, Michou L, Vaillancourt F, et al. Prevalence and Characteristics of Atypical Periprosthetic Femoral Fractures. J Bone Miner Res. 2019;34:83–92. https://doi.org/10.1002/jbmr.3584.
15. Bates BD, Walmsey DW, Vicente MR, et al. An international, cross-sectional survey of the management of Vancouver type B1 periprosthetic femoral
16. Kim MB, Cho JW, Lee YH, et al. Locking attachment plate fixation around a well-fixed stem in periprosthetic femoral shaft fractures. Arch Orthop Trauma Surg. 2017;137:1193–200. https://doi.org/10.1007/s00402-017-2745-4.

17. Mackenzie SA, Ng RT, Snowden G, et al. Periprosthetic atypical femoral fractures exist and are associated with duration of bisphosphonate therapy. Bone Joint J. 2019;101-B:1285–91. https://doi.org/10.1302/0301-620X.101B10.BJJ-2019-0599.R2.

18. Niikura T, Lee SY, Sakai Y, et al. Rare non-traumatic periprosthetic femoral fracture with features of an atypical femoral fracture: A case report. J Med Case Rep. 2015;9. https://doi.org/10.1186/s13256-015-0590-z.

19. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. J. Bone Miner. Res. 2010;25:2267–94.

20. Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment. Bone Jt J. 2017;99B:295–302. https://doi.org/10.1302/0301-620X.99B3.BJJ-2016-0276.R2.

21. Lee JYY, Soh T, Sen HT, et al. Bisphosphonate-associated peri-implant fractures: A new clinical entity? Acta Orthop. 2015;86:622–6. https://doi.org/10.3109/17453674.2015.1036339.

22. Githens M, Garner MR, Firoozabadi R. Surgical management of atypical femur fractures associated with bisphosphonate therapy. J Am Acad Orthop Surg. 2018;26:864–71.

23. Lee J-M, Kim T, Kim T. Treatment of Periprosthetic Femoral Fractures Following Hip Arthroplasty. Hip Pelvis. 2018;30:78. https://doi.org/10.5371/ hp.2018.30.2.78.

24. Lloyd AA, Giudovatz B, Redel C, et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A. 2017;114:8722–7. https://doi.org/10.1073/pnas.1704460114.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.